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Introduction
In patients with chronic and severe cancer 
pain, opioids can be used to control the 
baseline levels of pain by stable systemic 
exposure via different administration routes. 
Besides chronic pain, many patients with 
malignant disease experience breakthrough 
pain. Breakthrough pain is defined as a 
transitory exacerbation of pain experienced 
by the patient who has relatively stable and 
adequately controlled baseline pain.1 2 
It is typically characterised by a rapid 
onset, mostly within several minutes. Its 
duration varies widely, but for most patients 
exacerbation of pain diminishes within 1 h.2 
For the treatment of breakthrough pain, 
immediate release morphine and oxycodon 
preparations have been used. Until recently, 
there were no other possibilities for treating 
breakthrough pain. Both products are 
effective, but time until the effect is too 
long. Nowadays, immediate release fentanyl 
products are available.
Fentanyl is currently a widely used 
opioid in cancer pain. It is more potent 
than morphine, highly lipophilic and binds 
strongly to plasma proteins.3 Fentanyl 
patch for the treatment of continuous 
(cancer) pain is most often used. For 
immediate release, there are oromucosal 
products for transmucosal, buccal and 
sublingual administration routes. Apart 
from the oromucosal products, two 
nasal formulations of fentanyl have been 
developed. One is formulated with pectin 
(a polysaccharide obtained from plants) to 
improve mucosal adhesion while the other 
does not contain pectin.
In this brief overview, we describe the 
main pharmacokinetics and clinical aspects 
of these four administration routes for 
immediate release fentanyl preparations. 
These aspects may support selection of 
the optimal product for individual cancer 
patients.
Administration routes and 
pharmacokinetic characteristics
As mentioned above, there are various 
oromucosal products available. One 
is a fentanyl solution on a stick (oral 
transmucosal fentanyl citrate, Actiq), like a 
lollipop. By rubbing it over the mucosa for 
15 min, fentanyl is totally absorbed. The 
buccal tablet variants (Breakyl and Effentora) 
have to be placed between the upper gum 
and cheek above a molar tooth. Within 
30 min it will usually be absorbed by the 
mucosa. The sublingual fentanyl tablet 
(Abstral) is a rapidly disintegrating tablet that 
allows systemic delivery by the oral mucosa.
Fentanyl is also available in nasal sprays 
(PecFent and Instanyl), where the uptake 
of fentanyl takes place directly through the 
nasal mucosa. The spray uses the potential 
for rapid absorption resulting from the high 
vascularity and permeability of nasal tissue.
The bioavailability for the oromucosal 
products varies between 50% and 
70% (table 1). These relatively low 
bioavailabilities are explained by partial 
loss of fentanyl via first pass metabolism 
following intestinal absorption instead of 
direct uptake via the oral mucosa.3 The 
bioavailability of nasally delivered fentanyl 
is much higher (~90%).4 The small volume 
of the spray is directly absorbed by the 
nasal tissue and there is hardly any loss in 
the gastrointestinal tract by swallowing of 
fentanyl.
Pharmacokinetic studies in humans 
have been performed using immediate 
release fentanyl products. For the oromucosal 
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In palliative care, pain management is often hampered by episodes of breakthrough pain, characterised by a rapid 
onset and, on average, duration less than 1 h. Until recently, only immediate release morphine and oxycodon 
preparations were available for the treatment of these episodes but time until effect is too long for both of these 
drugs. Recently, immediate release fentanyl products have become available for the treatment of breakthrough pain. 
These products can be classified as oromucosal and nasal products. Both are absorbed rapidly by the mucosa, although 
the oromucosally delivered products are partly absorbed by the gastrointestinal tract and therefore reach maximum 
plasma levels somewhat slower (after 30–90 min) than the nasally delivered products (after ~15 min). In clinical 
placebo controlled studies, all new immediate release fentanyl products were proven to be effective from 15 min after 
administration in the treatment of breakthrough pain. The first studies comparing immediate release fentanyl with 
immediate release morphine or oxycodon also found superiority for the new fentanyl products.
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products, median Tmax varied between the 
sublingually delivered tablet, the buccal 
tablet and the transmucosal administration 
routes, where the first one was the fastest 
and the last one the slowest. In all studies, 
interindividual ranges in Tmax were quite 
large (range 30–240 min).5–9 Also, the 
terminal half life of fentanyl seems to 
vary between the various preparations, 
although this value depends on the 
moment of pharmacokinetic measurement. 
Unfortunately, most studies were done in 
small groups of healthy people (n=12–48). 
One study was performed in a group of just 
eight patients with metastatic cancer.9
Nasally delivered fentanyl has different 
characteristics compared with oromucosally 
delivered products. Median Tmax is much 
shorter, varying between 11 and 20 min.4–10 
There is also a much smaller interindividual 
range compared with the oromucosally 
delivered products.
Elimination of fentanyl by hepatic 
metabolism is slow compared with 
absorption and distribution of fentanyl. 
Following the absorption phase, 
distribution to tissue may contribute to the 
relatively short half life of 3 h, as reported 
for the Instanyl nasal spray. Thereafter, 
slow metabolism and redistribution may 
result in longer terminal half lives of 
5–22 h, as reported for the other products 
(table 1).
Clinical aspects
The four administration routes of immediate 
release products of fentanyl have been 
compared with placebo in clinical efficacy 
studies. All studied drugs were superior 
to placebo in terms of faster pain relief. 
Between 15 and 30 min after administration, 
a difference in pain intensity between the 
fentanyl products and placebo was found, as 
shown in figure 1.11 Two studies compared 
oromucosally delivered fentanyl with 
other immediate release opioids using a 
randomised, double blind study design.12 13 
Both studies showed more pain relief for the 
groups using oromucosal immediate release 
fentanyl formulations than for patients 
using morphine or oxycodon. Another 
study compared nasally delivered fentanyl 
with immediate release morphine and also 
found a significantly larger decrease in pain 
from 15 min after delivery for fentanyl.14 
Unfortunately, until now, there have been 
no double blind, randomised studies that 
have compared immediate release fentanyl 
products with each other.
Because of the long elimination time 
compared with the short absorption time 
of the fast acting fentanyl products, there 
is a risk of accumulation of fentanyl. This 
could lead to signs of overdosing such 
as respiratory depression, bradycardia, 
hypotension and nausea. However, this 
has not been reported to be relevant in 
the reported clinical trials, possibly due to 
limited and controlled fentanyl use in these 
studies.8–15 In clinical practice, the risk of 
accumulation needs attention, although it is 
advised that doses be titrated carefully.
Conclusions and perspectives
Nasally delivered fentanyl products are 
favourable to other immediate release 
products in terms of pharmacokinetic 
properties. Because of its short Tmax, fentanyl 
spray resembles the efficacy of intravenous 
fentanyl (the golden standard) most closely 
of all available products.
Oromucosally delivered preparations 
result in slower peak concentrations, and 
therefore time to effect may not be soon 
enough in all patients with breakthrough 
pain. Nevertheless, a significant part of 
fentanyl is absorbed transmucosally and 
will provide adequate serum concentrations 
within the first hour after administration. 
In line with these data, clinical trials 
have demonstrated a modest benefit in 
breakthrough pain relief over placebo and 
oral opioids. As interpatient variability is 
relatively large, with a wide range in Tmax, 
it may be useful to try different oromucosal 
preparations in clinical practice. In addition, 
patient preferences may play an important 
Table 1 Pharmacokinetic characteristics of fentanyl products
Administration route Product
Dose tested 
(μg)
Cmax 
(μg/l, mean)
T
max
 
(min, median)
Bioavailability (%) T
1/2
 
(h, terminal elimination) ReferenceTotal Gastrointestinal
Oromucosal OTFC Actiq 800 1.0 120 47 25 15.3 Vasisht5
800 1.3 91 18.3 Darwish7
Buccal Breakyl 800 1.3 90 71 20 19.0 Vasisht6
Buccal Effentora 400 1.0 47 65 17 14.4 Darwish7
800 1.7 60 14.4 Vasisht5
Sublingual Abstral 400 0.9 57 NA NA 5.4 Lennernäs9
800 1.4 30 10.1 Lister8
Nasal With pectin PecFent 100 0.4 20 NA NA 21.9 Davis3
No pectin Instanyl 100 1.0 11 >90 NA 3.0 Christrup4
0.6 12 Kaasa10
Key results from selected references are presented, and are not intended to provide a comprehensive overview of the data available. Results should be interpreted with care due to 
interindividual variability and differences between study populations and conditions.
NA, not available, OTFC, oral transmucosal fentanyl citrate.
Figure 1 Mean pain intensity difference versus time following administration of sublingual fentanyl (SLF) 100, 200 
or 400 µg compared with placebo. This figure was obtained with permission from Lennernäs and colleagues.11
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role in the selection of the optimal product 
for the individual patient. For patients with 
relatively ‘predictable’ breakthrough pain, 
such as the pain which occurs when starting 
daily activities, oromucosally delivered 
fentanyl preparations can be useful additions 
to the range of oral opioid products. It is 
likely that clear instructions to patients and 
nurses, and titration to the optimal dose for 
the individual patient, will improve clinical 
effectiveness.
Considering the available publications, it 
is important to stress that the vast majority 
of pharmacokinetic data were obtained 
from healthy adults or patients with 
minimal morbidity, and of normal weight, 
with normal renal and liver function, 
and without interacting co-medication. 
Pharmacokinetics may differ in patients 
with malignant disease. Moreover, these 
patients are often cachectic, use multiple 
drugs and can have organ failure. Apart from 
this, specific characteristics—for example, 
the amount of saliva—may affect the speed 
of the dissolving oromucosally delivered 
preparations and may therefore be a relevant 
factor in absorption and bioavailability. 
A dry mouth is a common side effect of 
opioids and is rather prevalent in the target 
population. Although optimal schedules 
for the use of immediate release opioids 
in these specific patients remain to be 
established, the immediate release fentanyl 
preparations have (substantially) increased 
our possibilities of treating breakthrough 
pain in cancer.
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Key messages
Various immediate release fentanyl products have 
been developed recently for the treatment of 
breakthrough cancer pain: products for oromucosal 
and nasal delivery. These products differ with 
respect to bioavailability and time to reach maximal 
plasma levels. Interindividual variability is large, even 
in healthy controls, especially for the oromucosal 
products. All drugs have proven to provide fast relief 
of breakthrough cancer pain in placebo controlled 
studies but insights into factors predicting a good 
response for the different products in individual 
patients have to be awaited.
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